Search Results - "Yusenko, Maria V"

Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events by Peterfi, Lehel, Yusenko, Maria V, Kovacs, Gyula, Beothe, Tamas

“…It is acknowledged that conventional renal cell carcinoma (cRCC), which makes up 85% of renal malignancies, is a highly vascular tumor. Humanized monoclonal…”
Get full text

FAPα and αSMA mark different subsets of fibroblasts in normal kidney and conventional renal cell carcinoma by Peterfi, Lehel, Yusenko, Maria V., Kovacs, Gyula, Beothe, Tamas

“…Several studies suggested a correlation between cancer associated fibroblasts (CAF) and cancer progression, but data on conventional renal cell carcinoma…”
Get full text

Molecular pathology of renal oncocytoma: A review by Yusenko, Maria V

“…Differentiating renal oncocytoma from its renal cell carcinoma (RCC) mimics, particularly chromophobe RCC, can be difficult, especially when limited tissue is…”
Get full text

High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas by Yusenko, Maria V, Kuiper, Roland P, Boethe, Tamas, Ljungberg, Börje, van Kessel, Ad Geurts, Kovacs, Gyula

“…The diagnosis of benign renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) based on their morphology remains uncertain in several cases. We…”
Get full text

Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824 by Yusenko, Maria V., Klempnauer, Karl-Heinz

“…•HDAC inhibitors suppress MYB activity.•HDAC inhibitor LAQ824 induces MYB degradation in AML cells.•LAQ824 disturbs the cooperation of MYB and p300.•LAQ824…”
Get full text

Molecular pathology of chromophobe renal cell carcinoma: A review by Yusenko, Maria V

“…The recognition of chromophobe renal cell carcinoma (RCC) among other distinct types of renal cell tumors (RCT) based on light‐microscopic features, such as…”
Get full text

Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner by Biyanee, Abhiruchi, Yusenko, Maria V, Klempnauer, Karl-Heinz

“…Recent studies have disclosed transcription factor MYB as a potential drug target for malignancies that are dependent on deregulated MYB function, including…”
Get full text

Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma by Yusenko, Maria V, Kovacs, Gyula

“…Aims:  The variation in cytoplasmic staining and growth pattern makes differential diagnosis of chromophobe renal cell carcinoma (RCC), especially from renal…”
Get full text

Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis by Yusenko, Maria V, Ruppert, Thomas, Kovacs, Gyula

“…Renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) display morphological and functional alterations of the mitochondria. Previous studies…”
Get full text

Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours by Yusenko, Maria V, Zubakov, Dmitry, Kovacs, Gyula

“…Due to overlapping morphology, malignant chromophobe renal cell carcinomas (RCC) and benign renal oncocytomas (RO) may pose a diagnostic problem. In the…”
Get full text

Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease by Kuntz, Eva, MD, Yusenko, Maria V., PhD, Nagy, Anetta, MD, Kovacs, Gyula, MD, PhD, DSc, FRCPath

“…Summary Renal cell carcinoma occurs at higher frequency in acquired cystic renal disease than in the general population. We have analyzed 4 tumors obtained…”
Get full text

IL6 Shapes an Inflammatory Microenvironment and Triggers the Development of Unique Types of Cancer in End-stage Kidney by Peterfi, Lehel, Yusenko, Maria V, Kovacs, Gyula

“…Chronic inflammation in end-stage kidney is associated with the development of pre-neoplastic lesions and renal cell tumors. The aim of this study was to…”
Get full text

M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma by Pusztai, Csaba, Yusenko, Maria V, Banyai, Daniel, Szanto, Arpad, Kovacs, Gyula

“…In spite of early detection, appoximately 15% of the small renal cell carcinomas (RCC) will develop metastasis within 5 years follow-up. The aim of this study…”
Get full text

Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma by Peterfi, Lehel, Banyai, Daniel, Yusenko, Maria V., Bjercke, Thea, Kovacs, Gyula

“…Background Approximately 15% of clinically localised conventional renal cell carcinoma (RCC) will develop metastasis within 5 years of follow-up. The aim of…”
Get full text

The Role of Genetic Analysis in Correct Diagnosis of Eosinophilic Variant of Chromophobe Renal Cell Carcinoma by Molnar, Agnes, Yusenko, Maria V, Kovacs, Gyula, Banyai, Daniel

“…It has been suggested that eosinophilic variant of chromophobe renal cell carcinoma (chRCC) with low chromosome number or lack of genomic alteration has an…”
Get full text

Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells by Yusenko, Maria V., Trentmann, Amke, Andersson, Mattias K., Ghani, Luca Abdel, Jakobs, Anke, Arteaga Paz, Mari-Francis, Mikesch, Jan-Henrik, Peter von Kries, Jens, Stenman, Göran, Klempnauer, Karl-Heinz

“…The master transcriptional regulator MYB is a key oncogenic driver in several human neoplasms, particularly in acute myeloid leukemia (AML) and adenoid cystic…”
Get full text

Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma by PETERFI, LEHEL, BJERCKE, THEA, YUSENKO, MARIA V., KOVACS, GYULA, BANYAI, DANIEL

“…Background/Aim: Despite early detection by widespread use of abdominal imaging more than 40% of patients with conventional renal cell carcinoma (RCC) will die…”
Get full text

Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner by Yusenko, Maria V., Biyanee, Abhiruchi, Andersson, Mattias K., Radetzki, Silke, von Kries, Jens P., Stenman, Göran, Klempnauer, Karl-Heinz

“…Studies of the role of MYB in human malignancies have highlighted MYB as a potential drug target for acute myeloid leukemia (AML) and adenoid cystic carcinoma…”
Get full text

A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells by Abdel Ghani, Luca, Yusenko, Maria V., Frank, Daria, Moorthy, Ramkumar, Widen, John C., Dörner, Wolfgang, Khandanpour, Cyrus, Harki, Daniel A., Klempnauer, Karl-Heinz

“…C/EBPβ has recently emerged as a pro-leukemogenic transcription factor that cooperates with oncoprotein MYB to maintain proliferation and differentiation block…”
Get full text

C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia by Yusenko, Maria V., Trentmann, Amke, Casolari, Debora A., Abdel Ghani, Luca, Lenz, Mairin, Horn, Melanie, Dörner, Wolfgang, Klempnauer, Stefan, Mootz, Henning D., Arteaga, Maria Francisca, Mikesch, Jan-Henrik, D’Andrea, Richard J., Gonda, Thomas J., Müller-Tidow, Carsten, Schmidt, Thomas J., Klempnauer, Karl-Heinz

“…Transcription factor MYB has recently emerged as a promising drug target for the treatment of acute myeloid leukemia (AML). Here, we have characterized a group…”
Get full text